# Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

> **NCT05331144** · PHASE2 · RECRUITING · sponsor: **Rong Zhang** · enrollment: 180 (estimated)

## Conditions studied

- Cognitively Normal Older Adults
- Hypertension
- Subjective Cognitive Decline
- Family History of Dementia

## Interventions

- **DRUG:** Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
- **OTHER:** PCP

## Key facts

- **NCT ID:** NCT05331144
- **Lead sponsor:** Rong Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-25
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05331144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05331144, "Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05331144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*